Financial Contrast: Caribou Biosciences (NASDAQ:CRBU) vs. Zura Bio (NASDAQ:ZURA)

Caribou Biosciences (NASDAQ:CRBU) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, earnings, dividends and profitability.

Valuation and Earnings

This table compares Caribou Biosciences and Zura Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16 million	14.17	-$148.12 million	($1.42)	-1.12
Zura Bio	N/A	N/A	-$99.35 million	($1.09)	-3.39

Zura Bio has lower revenue, but higher earnings than Caribou Biosciences. Zura Bio is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Caribou Biosciences and Zura Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%
Zura Bio	N/A	-55.74%	-48.07%

Volatility & Risk

Caribou Biosciences has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500.

Insider & Institutional Ownership

77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by company insiders. Comparatively, 12.4% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Caribou Biosciences and Zura Bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1	0	2	1	2.75
Zura Bio	1	1	3	1	2.67

Caribou Biosciences presently has a consensus target price of $8.67, suggesting a potential upside of 443.36%. Zura Bio has a consensus target price of $10.75, suggesting a potential upside of 190.54%. Given Caribou Biosciences’ stronger consensus rating and higher probable upside, equities analysts plainly believe Caribou Biosciences is more favorable than Zura Bio.

Summary

Zura Bio beats Caribou Biosciences on 7 of the 13 factors compared between the two stocks.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.